drugset / Trial / NCT05585398

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

NCT05585398

Phase 1 Completed 40 enrolled Merz Pharmaceuticals GmbH
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the distribution of IncobotulinumtoxinA (Xeomin) in healthy subjects at different volumes, concentrations and doses when administered intradermally and subcutaneously using different delivery methods (conventional needle and microneedles).

Timeline

Start
2022-10-19
Primary completion
2023-02-24
Completion
2023-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic Other

Indications

No indication recorded.